Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Radiol. Sep 28, 2024; 16(9): 446-452
Published online Sep 28, 2024. doi: 10.4329/wjr.v16.i9.446
Myelin oligodendrocyte glycoprotein-associated transverse myelitis after SARS-CoV-2 infection: A case report
Jian-Rong Zheng, Jun-Lei Chang, Jun Hu, Zhi-Jian Lin, Kai-Hua Lin, Bi-Hua Lu, Xu-Hui Chen, Zhi-Gang Liu
Jian-Rong Zheng, Jun Hu, Zhi-Jian Lin, Kai-Hua Lin, Xu-Hui Chen, Department of Neurology, Peking University Shenzhen Hospital, Shenzhen 518000, Guangdong Province, China
Jian-Rong Zheng, Department of Neurology, Shenzhen Xinhua Hospital, Shenzhen 518000, Guangdong Province, China
Jun-Lei Chang, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518000, Guangdong Province, China
Bi-Hua Lu, Department of Neurology, The Sixth People’s Hospital of Foshan Nanhai District, Foshan 528000, Guangdong Province, China
Zhi-Gang Liu, Laboratory of Functional Chemistry and Nutrition of Food, Northwest A&F University, Yangling 712100, Shaanxi Province, China
Co-corresponding authors: Xu-Hui Chen and Zhi-Gang Liu.
Author contributions: Zheng JR and Chen XH conceptualized and designed the case report, drafted the initial manuscript and revised it; Liu ZG contributed to the conception and design of the manuscript; Chang JL supervised and coordinated the manuscript; Hu J, Lin Z, Lin KH and Lu BH were involved in patient care and data collection; All authors reviewed and approved of the manuscript.
Supported by the Shenzhen University Teaching Reform Fund, No. JG2023166; the Shenzhen Science and Technology Innovation Commission Fund, No. JCYJ2022081802810022; and the Shenzhen Science and Technology Innovation Commission Basic Research Key Projects Fund, No. JCYJ20210324115800003.
Informed consent statement: Written consent has been acquired from the patient.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xu-Hui Chen, MD, Associate Chief Physician, Department of Neurology, Peking University Shenzhen Hospital, No. 1120 Lianhua Road, Futian District, Shenzhen 518000, Guangdong Province, China. xuhuichen@pkuszh.com
Received: April 2, 2024
Revised: August 23, 2024
Accepted: September 10, 2024
Published online: September 28, 2024
Processing time: 177 Days and 15.2 Hours
Abstract
BACKGROUND

Cases of myelin oligodendrocyte glycoprotein (MOG) antibody-related disease have a history of coronavirus disease 2019 infection or its vaccination before disease onset. Severe acute respiratory syndrome virus 2 (SARS-CoV-2) infection has been considered to be a trigger of central nervous system autoimmune diseases.

CASE SUMMARY

Here we report a 20-year male with MOG-associated transverse myelitis after a SARS-CoV-2 infection. The patient received a near-complete recovery after standard immunological treatments.

CONCLUSION

Attention should be paid to the evaluation of typical or atypical neurological symptoms that may be triggered by SARS-CoV-2 infection.

Keywords: Myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis; Myelin oligodendrocyte glycoprotein antibody-associated disease; SARS-CoV-2; COVID-19; Case report

Core Tip: Here we present a case of myelin oligodendrocyte glycoprotein-associated disease after severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. The patient received a near-complete recovery after standard immunological treatments. We suggest that attention should be paid to the evaluation of typical or atypical neurological symptoms that may be triggered by SARS-CoV-2 infection, and focus on the exclusion of coexisting autoimmune reactions or diseases.